Modified influenza viruses
AssigneeSeqirus Inc.
InventorsCharles MCGEE, Gregory EKBERG, Douglas WIDMAN
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the field of modified viruses and viral proteins. More particularly, this disclosure relates to modified haemagglutinin proteins, influenza viruses expressing such proteins and methods of making same
Claims30
A modified haemagglutinin (HA) protein comprising an amino acid sequence wherein one or more amino acid residues of a trimer interface region thereof is modified, wherein one or more of the modified amino acid residues are present in a lower region of a stalk domain and wherein the lower region of the stalk domain comprises amino acid residues at positions 377 to 397, 439 to 452, 26 to 46, and 325 to 335 of a full length HA protein of an influenza H2 subtype.
(canceled)
10-12. (canceled)
16-17. (canceled)
19-23. (canceled)
An isolated nucleic acid comprising a nucleotide sequence encoding a modified hemagglutinin (HA) protein comprising an amino acid sequence wherein one or more amino acid residues of a trimer interface region thereof is modified, wherein one or more of the modified amino acid residues are present in a lower region of a stalk domain and wherein the lower region of the stalk domain comprises amino acid residues at positions 377 to 397, 439 to 452, 26 to 46, and 325 to 335 of a full length HA protein of an influenza H2 subtype, or a nucleotide sequence complementary thereto.
26-28. (canceled)
An isolated influenza virus, comprising a hemagglutinin (HA) viral segment encoding a modified HA protein comprising an amino acid sequence wherein one or more amino acid residues of a trimer interface region thereof are modified, wherein one or more of the modified amino acid residues are present in a lower region of a stalk domain and wherein the lower region of the stalk domain comprises amino acid residues at positions 377 to 397, 439 to 452, 26 to 46, and 325 to 335 of a full length HA protein of an influenza H2 subtype.
32-48. (canceled)
A vaccine composition, wherein the vaccine composition comprises:
- (a) an isolated influenza virus comprising a hemagglutinin (HA) viral segment encoding a modified HA protein comprising an amino acid sequence wherein one or more amino acid residues of a trimer interface region thereof are modified, wherein one or more of the modified amino acid residues are present in a lower region of a stalk domain and wherein the lower region of the stalk domain comprises amino acid residues at positions 377 to 397, 439 to 452, 26 to 46, and 325 to 335 of a full length HA protein of an influenza H2 subtype, and a pharmaceutically acceptable carrier, diluent, or excipient;
- or
- (b) a modified HA protein comprising an amino acid sequence wherein one or more amino acid residues of a trimer interface region thereof are modified, wherein one or more of the modified amino acid residues are present in the lower region of the stalk domain and wherein the lower region of the stalk domain comprises amino acid residues at positions 377 to 397, 439 to 452, 26 to 46, and 325 to 335 of the full length HA protein of the influenza H2 subtype, and a pharmaceutically acceptable carrier, diluent, or excipient;
- or
- (c) an isolated nucleic acid comprising a nucleotide sequence encoding a modified HA protein comprising an amino acid sequence wherein one or more amino acid residues of a trimer interface region thereof is modified, wherein one or more of the modified amino acid residues are present in the lower region of the stalk domain and wherein the lower region of the stalk domain comprises amino acid residues at positions 377 to 397, 439 to 452, 26 to 46, and 325 to 335 of the full length HA protein of the influenza H2 subtype, and a pharmaceutically acceptable carrier, diluent, or excipient.
A method of eliciting an immune response and/or preventing and/or treating an influenza-associated disease, disorder, or condition in a subject, said method including the step of administering a therapeutically effective amount of:
- (a) an isolated influenza virus comprising a hemagglutinin (HA) viral segment encoding a modified HA protein comprising an amino acid sequence wherein one or more amino acid residues of a trimer interface region thereof are modified, wherein one or more of the modified amino acid residues are present in a lower region of a stalk domain and wherein the lower region of the stalk domain comprises amino acid residues at positions 377 to 397, 439 to 452, 26 to 46, and 325 to 335 of a full length HA protein of an influenza H2 subtype;
- (b) the modified HA protein;
- (c) an isolated nucleic acid encoding the modified HA protein;
- or (d) a vaccine composition comprising the isolated influenza virus, the modified HA protein, or the isolated nucleic acid encoding the modified HA protein to the subject to thereby elicit the immune response and/or prevent and/or treat the influenza-associated disease, disorder or condition in the subject.
51-56. (canceled)
A method of improving the growth, stability and/or manufacture of an influenza virus in cells, said method including the step of modifying the influenza virus to express a modified HA protein comprising an amino acid sequence wherein one or more amino acid residues of a trimer interface region thereof is modified, wherein one or more of the modified amino acid residues are present in a lower region of a stalk domain and wherein the lower region of the stalk domain comprises amino acid residues at positions 377 to 397, 439 to 452, 26 to 46, and 325 to 335 of a full length HA protein of an influenza H2 subtype.
58-76. (canceled)
Dependencies are inferred from the claim text.